According to Acumen Research and Consulting, the global uveitis treatment market valuation is poised to reach around US$ 860 million by 2026 and growing at noteworthy CAGR around 5.5 % throughout the forecast period 2019 to 2026.

The autoimmune eye disease Uveitis is thought to be common for only about 38 out of 100,000 individuals. It is frequently ignored because of this. After a great deal of delay, patients with uveitis are referred to an expert due to less knowledge of eye disease. This delays the early diagnosis of multiple ocular structures and outcomes in irreversible harm.

The report provides analysis of global Uveitis Treatment market for the period 2015-2026, wherein 2019 to 2026 is the forecast period and 2018 is considered as the base year.

Market Insights

Increasing uveitis incidence is the main driver of development. Anterior uveitis is 12 per 100.000 individuals annually, according to The College of Optometrists. Uveitis results in 30.000 new cases of blindness every year, representing nearly 10 per cent of the blind cases, on the basis of a study of medical records from California's communities. Increasing research and development operations in the ophthalmological sector have also resulted in elevated market growth. Globally, more and more clinical studies are being performed for treating eye inflammation. Many new stage III clinical trials for refractory post or intermediate uveitis are under development. For example, phase-III is being investigated as the normal Corticasteroid therapy for non-infectious upper, intermediate and panuveitis instances to determine the efficacy of mycophenolate mofetil and methotrexate. Another major factor that lead to efficient therapy of eye inflammation disorder is increased R&D activity for biological medicines. The demand for these medicines is anticipated to drive market development thereby. The incidence of uveitis with infectious etiologies also increases with increased instances of infectious illnesses. In developing nations, it is most prevalent. Around 50% of uveitis instances are triggered by infection, according to the Indian Journal of Inflammation Research. Even developing nations, owing to infectious etiology, are extremely prone to eye inflammation.

Treatment Type Stance

Due to its nature as the main therapy for patients with noninfectious uveitis, corticosteroids had the greatest market share of 2018. Corticosteroid medicines are very helpful for inflammation reduction. The Food and Drug Administration (FDA) approves various kinds of corticosteroid eye drops on the market. Eye drops, oral medicine or corticosteroid injections are often recommended by ophthalmologists. Corticosteroid implants also become more and more effective for persons with chronic inflammatory eye disorders. For example, the first FDA approved operating corticosteroid implant for the treatment of non-infective post-UV uveitis was Retisert produced in the United States by Bausch+Lomb. Over the forecast era monoclonal antibodies are expected to present a profitable CAGR due to fast biologic drug growth. Infliximab, Interferon, Daclizumab, Efalizumab Alefacept, Etanercept, are the most commonly-used biologic medications.

Disease Type Stance

Previous uveitis resulted the market in 2018 because adults and young people experienced elevated incidence of their disorder. More study on this subject also shows the growing age of this form of disease. For those with uveitis that is untreated and leads to sight loss and cataract, glaucoma and retinal oedema are at elevated danger. Later uveitis, due to the use of multiple drugs, is anticipated to show profitable development during the study period. Trivaris, for example, is a prevention corticosteroid of Allergan. The uveitis treating market is anticipated to be restrained by bad penetration of topical corticosteroids into the back of the eye. Median uveitis is expected to show important development over the prediction period, as it helps to prevent permanent structural harm to essential eye tissue. Moreover, the increasing incidence of multiple infectious diseases such as, leprosy, Lyme illness, tuberculosissyphilis, toxicaria and whipple illness is anticipated to lead to increased instances of uveitis.

Cause Stance

Due to the broad accessibility of different therapy choices, noninfectious uveitis produced important market revenues in 2018. The kinds of therapy used for noninfectious uveitis include corticosteroids, antibiotics, immunosuppressants and biologic medications. In the advanced areas in the globe, it is also mainly common. Due to increasing incidence of infectious illnesses in developing nations, infectious uveitis also retained a significant market share in 2018. It can influence different parts of the eye, from the front to the back. Syphilis, sarcoidosis and tuberculosis are reported by the American Academy of Ophthalmology in most patients identified as being tuberculosis.

Distribution Channel Stance

Due to a broad variety of alternatives for managing eye inflammation in hospitals, hospital pharmacies resulted the market in 2018 on a distribution channel. In addition, hospitals treat and care many patients and make hospital pharmacies a leading sector. The use of online pharmacies with a broad range of medicines and product details is anticipated to be important during the forecast period because of the increasing comfort of selecting online websites. In addition, a further factor that drives development is the increasing popularity of e-commerce distributors who offer medicinal products at discount rates.

Regional Stance

Due to the increasing incidence of non-infectious uveitis in the US, North America resulted the market in 2018. Furthermore, the promotion of regional development are ascribed to sophisticated healthcare equipment and to favourable refund policies. A great many drugs are accessible commercially in the US, further stimulating the country's demand.

As a result of increased R&D projects as well as increased healthcare spending, Europe produced important revenues in 2018. A important factor driving regional development is also the increase in aging population. Asia Pacific, however, has been expected to display profitable CAGR over the prediction era primarily because of the increasing prevalence and absence of sanitation of infectious illnesses in the developing area. Increased awareness of the different therapy options has resulted in elevated regional development.

Market Segmentation

Global Uveitis Treatment Market, By Treatment Type

• Monoclonal Antibodies
• Cycloplegic Agents
• Corticosteroids
• Immunosuppressant
• Antibiotics
• Antifungal
• Antivirals
• Analgesics

Global Uveitis Treatment Market, By Disease Type

• Intermediate Uveitis
• Posterior Uveitis
• Anterior Uveitis
• Panuveitis

Global Uveitis Treatment Market, By Cause

• Noninfectious
• Infectious

Global Uveitis Treatment Market, By Distribution Channel

• Retail
• Hospital
• Online

Global Uveitis Treatment Market, By Geography

• North America.
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa (MEA)

The market research study on “Uveitis Treatment Market - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026” offers detailed insights on global Uveitis Treatment market segments with market dynamics and their impact. The report also covers basic technology development policies.

The study offers an assessment of current trends in the sector and possibilities within each subsection from 2015-2026 and offers income development at the worldwide, regional, and nation levels. ARC has segmented the worldwide uveitis therapy report for this research on the grounds of the therapy type, illness type, cause, channel of delivery and area:

Key Players & Strategies

Knowledge of key market participants is increasingly being adopted by key producers such as new product development, mergers and acquisitions, and regional expansion, for example, EyePoint Pharmaceuticals, Inc. was obtained in 2018 by the USA. YUTIQ's FDA approval, a non-infectious uveitis treatment implantable that impacts the back of the eye.

Key players include Bausch & Lomb, Inc.; Allergan, Inc.; AbbVie, Inc.; Novartis AG; Eyegate Pharmaceuticals, Inc. Santen Pharmaceutical Co., Ltd; EyePoint Pharmaceuticals, Inc.

TABLE OF CONTENT